| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies. | Clin Cancer Res | 2008 | 0.89 |
| 2 | Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors. | Cancer Chemother Pharmacol | 2011 | 0.81 |
| 3 | Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors. | Cancer Chemother Pharmacol | 2015 | 0.77 |